Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A highly specific antibody against the core fucose of the N-glycan in IgG identifies the pulmonary diseases and its regulation by CCL2.
Kanto N, Ohkawa Y, Kitano M, Maeda K, Shiida M, Ono T, Ota F, Kizuka Y, Kunimasa K, Nishino K, Mukai M, Seike M, Azuma A, Harada Y, Fukuda T, Gu J, Taniguchi N. Kanto N, et al. Among authors: seike m. J Biol Chem. 2023 Dec;299(12):105365. doi: 10.1016/j.jbc.2023.105365. Epub 2023 Oct 20. J Biol Chem. 2023. PMID: 37865317 Free PMC article.
Standard versus low-dose nab-paclitaxel in previously treated patients with advanced non-small cell lung cancer: A randomized phase II trial (JMTO LC14-01).
Takeuchi S, Kubota K, Sugawara S, Teramukai S, Noro R, Fujikawa K, Hirose T, Atagi S, Minami S, Iida S, Kuraishi H, Aiba T, Minegishi Y, Matsumoto M, Seike M, Gemma A, Kawahara M; Japan-Multinational Trial Organization (JMTO). Takeuchi S, et al. Among authors: seike m. Cancer Med. 2023 Apr;12(8):9133-9143. doi: 10.1002/cam4.5652. Epub 2023 Feb 21. Cancer Med. 2023. PMID: 36807519 Free PMC article. Clinical Trial.
Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer.
Tozuka T, Noro R, Yoshida K, Takahashi S, Hirao M, Matsuda K, Kato Y, Nakamichi S, Takeuchi S, Matsumoto M, Miyanaga A, Kunugi S, Honda K, Adachi J, Seike M. Tozuka T, et al. Among authors: seike m. JTO Clin Res Rep. 2024 Mar 21;5(4):100668. doi: 10.1016/j.jtocrr.2024.100668. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38646155 Free PMC article.
A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small Cell Lung Cancer Study: (NEJ048A/NEXUS).
Miyanaga A, Asahina H, Watanabe S, Shukuya T, Tsubata Y, Hosomi Y, Sugawara S, Maemondo M, Okano T, Morita S, Matsuyama K, Kobayashi K, Seike M. Miyanaga A, et al. Among authors: seike m. Clin Lung Cancer. 2023 Jun;24(4):371-375. doi: 10.1016/j.cllc.2023.01.008. Epub 2023 Feb 1. Clin Lung Cancer. 2023. PMID: 36849264 Free article. Clinical Trial.
Perioperative Nivolumab in Resectable Lung Cancer.
Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M; CheckMate 77T Investigators. Cascone T, et al. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. N Engl J Med. 2024. PMID: 38749033 Clinical Trial.
342 results